UK and Ireland Neuroendocrine Tumour Society
Update on the NET news from ESMO in Copenhagen – the biggest congress so far attended by over 20 500 […]
NET-02: A multi-centre, randomised, open-label, phase II trial of nanoliposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line […]
The UK, through the National Cancer Research Institute (NCRI) Neuroendocrine Subgroup, is able to offer access to clinical trials to […]
September 2016 – Applications are invited for the Core – Derek Butler Fellowship. This is a 3-year full- time fellowship […]
